Home › Trials › NCT06466187

Investigating SGN-MesoC2 for advanced solid tumors

A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors

Phase 1 Interventional Seagen Inc. · NCT06466187

This study is testing a new drug called SGN-MesoC2 to see if it can help people with advanced solid tumors that haven't responded to other treatments.

Quick facts

PhasePhase 1
Study typeInterventional
Enrollment365 (estimated)
Ages18 Years and up
SexAll
SponsorSeagen Inc. Industry-sponsored
Drugs / interventionsradiation
Locations19 sites (Birmingham, Alabama and 18 other locations)
Trial IDNCT06466187 on ClinicalTrials.gov

What this trial studies

This clinical trial is focused on patients with advanced solid tumors that are either metastatic or locally advanced and cannot be treated with standard therapies. It evaluates the efficacy of an experimental drug called PF-08052666/SGN-MesoC2, which is an antibody-drug conjugate designed to target and kill cancer cells. The trial consists of three parts, assessing the drug's safety and effectiveness in patients who have relapsed or progressed after standard treatments. Participants must have measurable lesions and meet specific health criteria to be eligible.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with specific types of advanced solid tumors that are platinum-resistant and have not responded to standard therapies.

Not a fit: Patients with tumors that can be treated with standard care or those who have received more than two lines of cytotoxic systemic therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with difficult-to-treat advanced solid tumors.

How similar studies have performed: Other studies using antibody-drug conjugates have shown promising results, indicating potential for success with this novel approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Aged 18 years or older.
* Histologically- or cytologically-confirmed metastatic or locally advanced unresectable platinum-resistant ovarian cancer, NSCLC, pancreatic ductal adenocarcinoma, endometrial cancer, colorectal cancer, or mesothelioma, who have relapsed or progressed following standard therapies, or for which no standard therapies are available.
* An Eastern Cooperative Oncology Group performance status score of 0 or 1.
* At least 1 measurable lesion at baseline based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
* Archival tumor tissue or a fresh tumor biopsy during the screening period.
* Adequate hepatic, renal and bone marrow function.
* Participants must not have received more than 2 lines of cytotoxic systemic therapy in the metastatic setting (Parts B and C only).

Exclusion Criteria:

* Previously received or currently receiving any systemic anticancer therapy or focal radiotherapy within 4 weeks prior to the first dose of MesoC2 or within 2 weeks prior to the first dose of MesoC2 if the underlying disease had progressed on treatment.
* Prior anti-MSLN antibody or MSLN-directed ADC (Part C only).
* Unresolved toxicities from prior therapy greater than NCI CTCAE v5.0 grade 1 at the time of study treatment (except alopecia).
* Inadequate hepatic dysfunction, renal function, or hematologic abnormalities.
* Previously untreated brain metastases. Participants who received radiation or surgery for brain metastases are eligible if therapy was completed at least 4 weeks prior to study treatment initiation, and there was no evidence of central nervous system progression nor requirements for chronic corticosteroid therapy

Where this trial is running

Birmingham, Alabama and 18 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Carcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic AdenocarcinomaColorectal NeoplasmsMesotheliomaOther Solid TumorsEndometrialNSCL
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.